Seqirus Announces New Advances in Cell-Based Influenza Vaccine Technology

As Seqirus continues to manufacture and distribute egg-based vaccines worldwide, discover how cell-based influenza vaccine technology is a significant advancement in protection.

Seqirus, a leading innovator in the field of protection against influenza, announced its decision to manufacture its cell-based flu vaccine (FLUCELVAX® TETRA) technology using candidate vaccine viruses ( CVV) for the four strains recommended by the World Health Organization (WHO). season, making the whole production process based on cells.

The company will file data with the European Medicines Agency (EMA) in support of this decision as part of the annual update requirement of the 2019/20 strains.

Advancing influenza vaccine technology

CVVs are provided each season by the WHO Global Influenza Surveillance and Response System (GISRS) and badociated laboratories. Seeds made from these CVVs are used to grow large amounts of virus, either in eggs or cells, allowing the mbad production of influenza vaccine corresponding to the strains recommended by WHO.

According to a recent study, which badessed the degree of match of egg and cell-based CVVs with the seasonal viral strain circulating in the last 12 seasons, cell-based H3N2 CVVs were closer to the circulating virus. only eggs. CVV H3N2 based on

"Egg-based vaccines are the standard of care and continue to play a critical role in the fight against influenza, but it's important to constantly evolve in vaccine design," said Gordon Naylor. President of Seqirus.

"As we continue to manufacture and distribute egg-based vaccines worldwide, cell-based influenza vaccines represent significant progress in protecting against the flu. Seqirus is proud to continue to innovate this promising technology as part of its leading role in preventing influenza and pandemic preparedness.

What do you know about Seqirus?

Seqirus, the world's largest manufacturer of cell-based influenza vaccines, produces FLUCELVAX TETRA at its plant in Holly Springs, North Carolina, USA. The Holly Springs facility was purpose built in partnership with the US Biomedical Research and Advanced Development Authority (BARDA) to address pandemic threats and develop a vaccine technology against the flu.